Holen Sie sich die Stockscreener-App
57.64
0.07%
-0.0261
Schlusskurs vom Vortag:
$57.67
Offen:
$57.6
24-Stunden-Volumen:
394.86K
Relative Volume:
0.16
Marktkapitalisierung:
$14.28B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$833.42M
KGV:
19.11
EPS:
3.0172
Netto-Cashflow:
$917.69M
1W Leistung:
-1.54%
1M Leistung:
+6.58%
6M Leistung:
+36.02%
1J Leistung:
+50.55%
1-Tages-Spanne:
$56.95
$58.18
1-Wochen-Bereich:
$56.95
$59.72
52-Wochen-Spanne:
$33.76
$59.72
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
57.64 | 14.29B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
520.68 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.99 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.68 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.22 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.66 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Adagene Inc. Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - marketscreener.com
Adagene Receives Milestone Payment From Exelixis - marketscreener.com
Exelixis at Citigroup summit: building a second growth engine - Investing.com
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
A cancer-drug milestone brings Adagene a $2 million payment - Stock Titan
Transcript : Exelixis, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 11 - marketscreener.com
Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026) - JD Supra
Exelixis at Wells Fargo conference: zanzalintinib takes center stage By Investing.com - Investing.com Canada
Exelixis Stock Price Forecast. Should You Buy EXEL? - StockInvest.us
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Exelixis stock hits all-time high at 57.68 USD By Investing.com - Investing.com Australia
EXEL - Finviz
Exelixis stock hits all-time high at 57.68 USD - Investing.com
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2026 - BioSpace
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire
Exelixis secures Cabometyx exclusivity with patent win - BioWorld News
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data - Seeking Alpha
Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win - Law360
Exelixis wins appeals court ruling upholding key patents, FDA approval barred until at least Jan 15, 2030 - TradingView
Exelixis Wins Appeal in Patent Case Against MSN Laboratories - marketscreener.com
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win - GuruFocus
Exelixis Says U.S. Court Of Appeals For Federal Circuit Affirms Key Portion Of 2024 Judgment In Co's Favor - TradingView
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories - Business Wire
Exelixis Preserves Win Over MSN on Cabometyx Cancer Drug Patents - Bloomberg Law News
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Through Biotechnology with High Return on Equity - DirectorsTalk Interviews
Strong Sales, Earnings Send Exelixis Shares Higher - Yahoo Finance
Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition - Trefis
Here's Why Exelixis (EXEL) is a Strong Value Stock - Eastern Progress
NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL - MarketBeat
51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC - MarketBeat
BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL - MarketBeat
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law - The Daily Tribune News
FARALLON CAPITAL MANAGEMENT, L.L.C. Buys More Exelixis Inc (EXEL - GuruFocus
BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" - MarketBeat
Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXEL - MarketBeat
Out of sight, out of work? What’s driving remote job cuts - BioSpace
Investigation launched into EXELIXIS officers f... - Pluang
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - PR Newswire
Exelixis Inc : BMO Initiates Coverage With Ma - Moomoo
EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54 - Bitget
BMO initiates Exelixis stock at Market Perform, cites patent cliff By Investing.com - Investing.com Australia
EXEL Initiates Coverage On BMO Capital -- Price Target Announced at $54.00 - GuruFocus
BMO initiates Exelixis stock at Market Perform, cites patent cliff - Investing.com
JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL - MarketBeat
AQR Capital Management Trims Exelixis Inc (EXEL) Stake -- Shares Trade 16% Above GF Value - GuruFocus
EXEL Looks 16.3% Overvalued on GF Value™ - GuruFocus
Pallas Capital Advisors LLC Invests $1.67 Million in Exelixis, Inc. $EXEL - MarketBeat
27,109 Shares in Exelixis, Inc. $EXEL Purchased by Grandfield & Dodd LLC - MarketBeat
Exelixis (EXEL) Climbs 2.48% as Shares Test Key Resistance at $55.14ATR Stop - vinanet.vn
Exelixis (EXEL) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):